Publisher Full Text
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.Antiviral Res. 2020 06; 178:104787.AR
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
Links
MeSH
Pub Type(s)
Journal Article
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
32251768
Clinical Trial Links
Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms
Citation
Caly, Leon, et al. "The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro." Antiviral Research, vol. 178, 2020, p. 104787.
Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, 178, 104787. https://doi.org/10.1016/j.antiviral.2020.104787
Caly L, et al. The FDA-approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Res. 2020;178:104787. PubMed PMID: 32251768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
AU - Caly,Leon,
AU - Druce,Julian D,
AU - Catton,Mike G,
AU - Jans,David A,
AU - Wagstaff,Kylie M,
Y1 - 2020/04/03/
PY - 2020/03/18/received
PY - 2020/03/27/revised
PY - 2020/03/29/accepted
PY - 2020/4/7/pubmed
PY - 2020/7/7/medline
PY - 2020/4/7/entrez
SP - 104787
EP - 104787
JF - Antiviral research
JO - Antiviral Res
VL - 178
N2 - Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
SN - 1872-9096
UR - https://www.unboundmedicine.com/medline/citation/32251768/full_citation
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0166-3542(20)30201-1
DB - PRIME
DP - Unbound Medicine
ER -